AMD treatment with PROMACULA®
PROMACULA® is the gold standard for treating AMD.
The formulation fully conforms to the AREDS2 study. PROMACULA® premium products from Lenus Pharma are manufactured in accordance with the pharmaceutical standard (pharmaceutical GMP). This ensures continuous checks from the raw materials up to the finished product and maximum safety for all patients.
„The AREDS2-compliant combination of high-dose vitamin C, vitamin E and zinc, concerns a treatment which cannot be replaced through dietary means. PROMACULA® lutein offers an AMD treatment which has the precise composition of the AREDS-2 formulation and thus corresponds with the latest scientific knowledge.”
(Professor Dr. Stur)
How does PROMACULA® work and what successes have there been with this treatment?
Provided that PROMACULA® is taken regularly, according to the results of clinical studies, it can slow down the advancement of AMD, age-related macular degeneration.
- Because PROMACULA® is fully compliant with the AREDS2 formulation, it meets the criteria for evidence-based AMD treatment.
- All ingredients and dosages comply with the experience and positive results of many years of research.
The four PROMACULA® preparations are individually tailored to patient needs.
100% AREDS2. Tailor-made.
PROMACULA® lutein is a classic for AMD, which has proven itself for more than 10 years of AMD treatment, and is still valued today.
Taking PROMACULA® areds2 regularly can reduce the risk of AMD progression. This has been clinically proven in the AREDS2 study.
PROMACULA® max! makes age-related AMD just as treatable as diabetic retinopathy. The added bonus of folic acid and antioxidants optimally supports the eye’s protective system. This formulation is also perfectly suited to diabetics. People with dysphagia (difficulties swallowing) can take the preparation without a problem, as the capsules can be opened.
Due to meeting high quality standards, PROMACULA® omega can slow down the advancement of AMD. The Omega-3 fatty acids it contains help with “dry eyes ” (Sicca syndrome or Sjogren’s syndrome).
Studies substantiate: Only AREDS2 compliant preparations can slow down AMD when taken regularly.
Further treatment options
-
Treatment of dry macular degeneration using 2RTTM laser
Treatment of dry macular degeneration can be treated in the early stages with the 2RTTM laser. This ultra-short pulsed laser, developed in cooperation with London’s Moorfields Hospital, stimulates a natural and biological healing response precisely on the retina. This allows the retina to regenerate. Dry AMD can thus be stopped for a certain period of time. The change to aggressive wet AMD can be prevented. Used very early, the first signs can even be reversed.
-
Treatment of wet macular degeneration using anti-VEGF therapy
Wet degeneration of the macula can be treated with anti-VEGF therapy. Even though this form of eye disease cannot be cured so far, it is still possible to stop or slow it down. For this purpose, the inhibition of new vessel formation is the first priority with anti-VEGF therapy.
-
Intravitreal injection
In intravitreal injection, VEGF inhibitors are injected into the vitreous of the affected eye by specially trained ophthalmologists after prior anesthesia in a sterile surgical area. The effect of these inhibitors is that they slow down the growth factor vascular endothelial growth (VEGF). In the eye, for example, VEGF promotes the formation of diseased blood vessels and their permeability. There is a risk of edema formation.
In order to slow down this pathological process, several injections are required within an individual therapy scheme. Often, a permanent treatment of this kind cannot be avoided.
Intravitreal injection, also called ophthalmic injection, is used in the following cases
- wet age-related macular degeneration (AMD)
- the rare choroidal neovascularization (cCNV)
- retinal vein occlusion (RVV)
- diabetic macular edema (DME)
-
Photodynamic therapy (PDT)
Photodynamic therapy (PDT) as a special laser technique with a “cold” beam, is used in pathologic myophia (PM) or also the rare choroidal neovascularization (cCNV). Sometimes also in diabetic retinopathy. First, a light-sensitive dye that accumulates in the diseased blood vessels of the eye is injected into the brachial vein through a cannula. The cold laser light activates the co-injected effective substance. In this way, diseased vessels can be selectively obliterated. Healthy vessels remain unharmed.
-
Laser coagulation
Laser coagulation also scleroses diseased and leaking blood vessels. But with a hot laser beam. In this way, the finest holes in the retina can be closed and detachments can be treated. Beforehand, the pupils must be dilated. This procedure is often used for diabetic retinopathy.
-
Vitrectomy
Vitrectomy, a surgical procedure, involves removing the vitreous and treating the retina with a laser, for example. Pars plana vitrectomy (PPV) has established itself as a successful method here. It is used in cases of diabetic retinopathy and when there is a vitreous hemorrhage.
Minimise the risk of AMD progressing. Taking PROMACULA® early on protects your eyesight.
